A triple-therapy regimen for eradication of Helicobacter pylori was found to be safe for adolescents, according to the results of a prospective, multicenter study that were published in Scientific Reports.
Students (N=151) attending junior high school in Japan in 2016 were recruited for this study. The students were tested for H pylori through urine and stool samples. Those who were positive (n=31) underwent a triple-therapy eradication regimen consisting of vonoprazan fumarate (20 mg), amoxicillin (750 mg), and clarithromycin (200 mg) twice a day for 7 days. Students provided stool samples at 1 to-2 days and again at 8 to 12 weeks after therapy. Eradication was assessed at 8 to 12 weeks by 13C-urea breath test.
A total of 29 students provided the first stool sample, 26 the second, and 19 the third. Of the students who provided all samples, 3 were considered treatment failures.
Among the 16 students with treatment success and sufficient data, 9 were boys aged median 15.6 years.
Following eradication, the proportion of Actinobacteria was significantly reduced (P =.006924) but increased at 8 to 12 weeks (P =.047065) to a similar level as before treatment (P =.214554). Coriobacteriaceae decreased in abundance after eradication (P =.008656).
After eradication, significant reductions to phylogenetic richness (P =.003), microbiota diversity (P =.023), and microbial species richness (P =.003) were observed. At 8 to 12 weeks, significant differences were not observed, indicating microbiota diversity recovery over time.
The adverse events reported were abdominal pain among 2 students and diarrhea in 1 student.
This study was limited by its low sample size, its low retention rate, and the choice to not include a control condition with which to make comparisons.
These data indicated a triple-therapy regimen of vonoprazan fumarate, amoxicillin, and clarithromycin for the eradication of H pylori was safe for use among adolescents. No evidence of alterations to the overall diversity of gut microbiota was observed, justifying additional longer-term studies among a larger population.
Disclosure: Multiple authors declared affiliations with industry. Please refer to the original article for a full list of disclosures.
Kakiuchi T, Yamamoto K, Imamura I et al. Gut microbiota changes related to Helicobacter pylori eradication with vonoprazan containing triple therapy among adolescents: a prospective multicenter study. Sci Rep. 2021;11(1):755. doi:10.1038/s41598-020-80802-3